Dainippon Sumitomo To Use iPS Cells To Test For Potential Orphan Drugs
This article was originally published in PharmAsia News
Executive Summary
Dainippon Sumitomo Pharma said it plans to use induced pluripotent stem cells in efficacy tests for potential orphan drugs by screening potential treatments to identify compounds with potential.